Post-hoc analysis of data from 3,330 patients who received 5 mg or 10 mg tofacitinib twice daily for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in phase II and III studies reveals that tofacitinib treatment was associated with rapid and sustained alleviation of pain. Overall, improvements were seen in all pain assessments (including unidimensional pain measures and individual pain components of multidimensional measures) with tofacitinib treatment compared with placebo. Tofacitinib reduced pain at both dosages and regardless of inadequate response to previous treatments.